PNH in AA and MDS

PNH clones in AA/MDS occur frequently, with important prognostic and therapeutic implications

PNH cells (granulocytes) are common in bone marrow disorders2,3

  • Approximately 70% of patients with AA have PNH clones2*
  • As many as 42% of patients with MDS have PNH clones3*

Evaluate your AA patients for PNH at diagnosis and annually, as clones may expand rapidly and unpredictably over time.4,5


Conduct high-sensitivity flow cytometry on peripheral blood in addition to bone marrow aspirate to confirm the presence of PNH during evaluation for AA, MDS, or unexplained cytopenias

*0.003% PNH cell threshold.

References: 1. NCCN Guidelines. Version 1; 2009. National Comprehensive Cancer Network. 2. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314. 3. Ishikawa T, Tohyama K, Nakao S, et al. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55-CD59- blood cells predicts platelet response. Int J Hematol. 2007;86:150-157. 4. Parker C, Omine M, Richards S, et al; for the International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709. 5. Maciejewski JP, Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma. 2004;45:433-440.